Summary
Tolterodine is a new competitive muscarinic receptor antagonist developed for the treatment of the unstable bladder. A total of 242 patients were enrolled in a multicenter, multinational, randomized, double-blind, placebo-controlled study conducted over a period of 4 weeks in patients with detrusor overactivity and symptoms of frequency, urgency, and urge incontinence. The objective of the study was to compare the efficacy and safety of tolterodine given at 1 or 2 mg b.i.d. versus placebo. At week 4 a statistically significant increase in the volume at first contraction (p = 0.030) and maximal cystometric capacity (p = 0.034) was only in the tolterodine 2 mg b.i.d. group. Tolterodine was safe and generally well tolerated. The incidence of dry mouth, as the most commonly reported adverse event, was only 9% and of mild to moderate intensity.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Andersson K-E (1988) Current concepts in the treatment of disorders of micturition. Drugs 35: 477–494
Couillard DR, Webster GD (1995) Detrusor instability. Urol Clin North Am 22: 593–612
Kelleher CI, et al (1994) Antichoinergic therapy: the need for continued surveillance (abstract 59). Neurol Urdoyn 13: 4
Lockhart JL, Shessel F, Weinstein D, Politano VA (1982) Urodynamics in women with stress and urge incontinence. Urology 20: 333–336
Nilvebrant L, et al (1997) Tolterodine — a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data. Life Sci (in press)
Ouslander et al (1988) Pharmacokinetics and clinical effects of oxybutynin in geriatric patients. J Urol 140: 47–50
Thüroff J, et al (1991) Randomised, double-blind, multicentre trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J Urol 145: 813–817
Yarker YE, Goa KL, Fitton A (1995) Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 6: 243–262
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Jonas, U., Höfner, K., Madersbacher, H. et al. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. World J Urol 15, 144–151 (1997). https://doi.org/10.1007/BF02201987
Issue Date:
DOI: https://doi.org/10.1007/BF02201987